BeyondSpring (BYSI) Income from Continuing Operations (2016 - 2026)
BeyondSpring (BYSI) posted Income from Continuing Operations of 2351000.0 for Q1 2026, down 286.04% sequentially from 609000.0 in Q4 2025, and up 9.02% YoY from 2156543.84 in Q1 2025.
BeyondSpring (BYSI) Income from Continuing Operations (2016 - 2026) Analysis & Trends
BeyondSpring has reported Income from Continuing Operations for 9 years, with the latest figure at 2351000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 9.02% year-over-year to 2351000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6581000.0 (up 11.45% YoY) and the FY2025 annual result came in at 6814000.0, up 1.65% from the prior year.
- Income from Continuing Operations eased to 2351000.0 in Q1 2026 per BYSI's latest filing, from 609000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 18000.0 in Q4 2024 and troughed at 2651000.0 in Q2 2024.
- A 3-year average of 1788111.11 and a median of 2080000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 29.16% in 2025, down 3483.33% in 2025.
- Over 3 years, Income from Continuing Operations stood at 18000.0 in 2024, then tumbled by 3483.33% to 609000.0 in 2025, then slumped by 286.04% to 2351000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2351000.0, 609000.0, and 1743000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | -1.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.75 Mn |
| Mar 31, 2026 | -2.35 Mn |
| Dec 31, 2025 | -609,000.00 |
| Sep 30, 2025 | -1.74 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | -2.58 Mn |
| Dec 31, 2024 | 18,000.00 |
| Sep 30, 2024 | -2.22 Mn |
| Jun 30, 2024 | -2.65 Mn |
| Mar 31, 2024 | -2.08 Mn |
| Dec 31, 2021 | 6.42 Mn |
| Sep 30, 2021 | -20.14 Mn |
| Jun 30, 2021 | -19.89 Mn |
| Mar 31, 2021 | -17.44 Mn |
| Dec 31, 2020 | -4.97 Mn |
| Sep 30, 2020 | -15.18 Mn |
| Jun 30, 2020 | -13.60 Mn |
| Mar 31, 2020 | -16.66 Mn |
| Dec 31, 2019 | -6.59 Mn |
| Sep 30, 2019 | -9.82 Mn |